59 related articles for article (PubMed ID: 3384392)
1. Deferoxamine mesylate inhibits bacterial growth in vivo.
Ando Y; Akaike T; Inoue M; Horisawa Y; Yamada Y; Uekawa K; Fujise R; Araki S
Hokkaido Igaku Zasshi; 1988 Mar; 63(2):207-12. PubMed ID: 3384392
[TBL] [Abstract][Full Text] [Related]
2. Induction of apoptosis by iron depletion in the human breast cancer MCF-7 cell line and the 13762NF rat mammary adenocarcinoma in vivo.
Jiang XP; Wang F; Yang DC; Elliott RL; Head JF
Anticancer Res; 2002; 22(5):2685-92. PubMed ID: 12529982
[TBL] [Abstract][Full Text] [Related]
3. Use of a marker plasmid to examine differential rates of growth and death between clinical and environmental strains of Vibrio vulnificus in experimentally infected mice.
Starks AM; Bourdage KL; Thiaville PC; Gulig PA
Mol Microbiol; 2006 Jul; 61(2):310-23. PubMed ID: 16856938
[TBL] [Abstract][Full Text] [Related]
4. The importance of pharmacodynamic properties in treatment of penicillin resistant Streptococcus pneumoniae.
Knudsen JD
Dan Med Bull; 2000 Nov; 47(5):313-27. PubMed ID: 11155659
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma.
Wang F; Elliott RL; Head JF
Anticancer Res; 1999; 19(1A):445-50. PubMed ID: 10226580
[TBL] [Abstract][Full Text] [Related]
6. [Role of iron and a siderophore in the development of bacterial infections in the mouse: the study of two bacteria and three routes of inoculation].
Gauthier Y; Aulagnier G; Isoard P
C R Seances Acad Sci III; 1982 Dec; 295(12):675-8. PubMed ID: 6820299
[TBL] [Abstract][Full Text] [Related]
7. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin.
Hoke EM; Maylock CA; Shacter E
Free Radic Biol Med; 2005 Aug; 39(3):403-11. PubMed ID: 15993339
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.
Hoyes KP; Jones HM; Abeysinghe RD; Hider RC; Porter JB
Exp Hematol; 1993 Jan; 21(1):86-92. PubMed ID: 8417963
[TBL] [Abstract][Full Text] [Related]
9. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
10. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
Richardson DR; Ponka P
J Lab Clin Med; 1994 Nov; 124(5):660-71. PubMed ID: 7964124
[TBL] [Abstract][Full Text] [Related]
11. The identification of 2, 3-dihydroxybenzoic acid as a potentially useful iron-chelating drug.
Graziano JH; Grady RW; Cerami A
J Pharmacol Exp Ther; 1974 Sep; 190(3):570-5. PubMed ID: 4416298
[No Abstract] [Full Text] [Related]
12. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
Voest EE; van Acker SA; van der Vijgh WJ; van Asbeck BS; Bast A
J Mol Cell Cardiol; 1994 Sep; 26(9):1179-85. PubMed ID: 7815460
[TBL] [Abstract][Full Text] [Related]
13. Iron and iron chelating agents modulate Mycobacterium tuberculosis growth and monocyte-macrophage viability and effector functions.
Cronjé L; Edmondson N; Eisenach KD; Bornman L
FEMS Immunol Med Microbiol; 2005 Aug; 45(2):103-12. PubMed ID: 16051061
[TBL] [Abstract][Full Text] [Related]
14. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of vascular endothelial growth factor production by iron chelators.
Beerepoot LV; Shima DT; Kuroki M; Yeo KT; Voest EE
Cancer Res; 1996 Aug; 56(16):3747-51. PubMed ID: 8706019
[TBL] [Abstract][Full Text] [Related]
16. Effects of kojic acid on oxidative damage and on iron and trace element level in iron-overloaded mice and rats.
Kotyzová D; Eybl V; Koutenský J; Brtko J; Glattre E
Cent Eur J Public Health; 2004 Mar; 12 Suppl():S41-4. PubMed ID: 15141975
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase.
Green DA; Antholine WE; Wong SJ; Richardson DR; Chitambar CR
Clin Cancer Res; 2001 Nov; 7(11):3574-9. PubMed ID: 11705879
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells.
Fan L; Iyer J; Zhu S; Frick KK; Wada RK; Eskenazi AE; Berg PE; Ikegaki N; Kennett RH; Frantz CN
Cancer Res; 2001 Feb; 61(3):1073-9. PubMed ID: 11221835
[TBL] [Abstract][Full Text] [Related]
19. Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.
Kontoghiorghes GJ
Mol Pharmacol; 1986 Dec; 30(6):670-3. PubMed ID: 3785144
[TBL] [Abstract][Full Text] [Related]
20. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines.
Chong TW; Horwitz LD; Moore JW; Sowter HM; Harris AL
Cancer Res; 2002 Dec; 62(23):6924-7. PubMed ID: 12460908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
